Skip to main content

Marie Sklodowska-Curie’s Innovative Training Network (ITNs)

Innovative Training Networks (ITNs) drive scientific excellence and innovation. They bring together universities, research institutes and other institutions from the non-academic sector to train researchers up to the doctoral level.

  • TArgeting Platelet Adhesion receptors in thrombosiS (TAPAS):  
    TAPAS will position Europe at the forefront of innovative research to prevent thrombosis and thromboinflammation, and will train a uniquely-qualified cohort of ESRs in a highly intersectorial and multi-disciplinary programme that will equip them with the knowledge and transferable skills required in the broad biomedical sector. In TAPAS program, an original and innovative approach will be undertaken to find new ways to target thrombosis through co-operation of academic experts in distinct disciplines with key skills from the private sector.
  • Drug repurposing and discovery multidisciplinary training Network DRUGTrain:   
    The EU-funded DRUGtrain project will develop an ideal multidisciplinary research model to improve drug repurposing and compound development strategies, for example, for autosomal dominant polycystic kidney disease. The initiative will use bioinformatics and chemoinformatics to identify potential drug targets and drugs that could be repurposed. Screening and testing tasks will also be carried out on the drugs in advanced "in vitro" and "in vivo" models, until the trials are carried out with the new treatment strategies. DRUGtrain also makes contacts to foster collaboration between business, academia and patient organisations.
  • Deconstructing and Rewiring RNA-RBP regulatory networks:  
    RBP-ReguNet has been conceived to leverage these new discoveries to identify druggable targets for a range of untreatable diseases, including cancer, neurological disorders, liver diseases and infectious disease. The objetive of RBP-ReguNet is to create a high-level training program based on basic research but with a strong impact on clinical translation. This network of excellence will push the boundaries of knowledge in the protein-RNA interactions universe, and at the same time provide the next generation of students with the skills to become future leaders in the field.
  • Targeting Circadian Clock Dysfunction in Alzheimer’s Disease: 
    Many genes responsible for the circadian clock are aberrantly expressed in Alzheimer’s disease, rendering it a putative drug target. The TClock4AD project, funded by the Marie Skłodowska-Curie Actions programme, aims to develop novel drugs that target the circadian clock. Researchers will investigate the molecular mechanisms that govern circadian rhythms in Alzheimer’s disease, identify therapeutic targets and develop rationally designed compounds, which will be tested for their efficacy in innovative screening models.
  • Innovative ligands for nuclear receptors to eradicate cancer relapse (eRaDicate):
    The aim of the “eRaDicate” international, multidisciplinary, and intersectoral cancer drug research and development programme is to empower 10 young scientists to become specialists in cancer research and drug development, while developing new therapies against cancer stem cell-driven relapse and metastasis. Nuclear receptors, such as retinoic acid receptor (RAR) and vitamin D receptor (VDR), play key roles in many hallmarks of cancer and constitute effective targets for modern cancer therapy.